GWIIRT: Gulf War Illness Inflammation Reduction Trial

Sponsor

Minneapolis Veterans Affairs Medical Center (U.S. Fed)

Overall Status

Completed

CT.gov ID

NCT02506192

Collaborator

United States Department of Defense (U.S. Fed)

Enrollment

Location

Arms

80.2

Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes measures include changes from baseline levels of GWI-associated biomarkers of inflammation in peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and HRQOL with respect to mental functioning.

Condition or Disease	Intervention/Treatment	Phase
Chronic Inflammation Chronic Pain Fatigue Cognitive Impairment	Drug: Modified-Release Prednisone Drug: Placebo	Phase 2

Detailed Description

During Desert Shield and Desert Storm (Aug 2, 1990 to July 31,1991) 696,841 United States Military personnel were deployed to the Kuwaiti Theater of Operations. Today approximately one-third of those veterans are suffering from GWI, an unexplained chronic multi-symptom illness. Evidence of chronic inflammation in veterans with GWI has emerged from previous observational studies. The goal of this trial is to determine if reducing the GWI-associated chronic inflammation is an effective treatment for GWI. This is a randomized, two group, placebo controlled, double blind clinical trial. The treatment group will receive a low dose (2x5mg) once a day of delayed-release prednisone (Rayos) for 8 weeks. The placebo group will receive matching placebo (2x5mg) once a day for 8 weeks. The primary outcome measure for this clinical trial is a change from baseline of HRQOL with respect to physical functioning and symptoms. The secondary outcome measures include changes from baseline of peripheral blood levels of GWI-associated biomarkers of inflammation, changes from baseline of GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and a change from baseline of HRQOL with respect to mental functioning.

Study Design

Study Type:

Interventional

Actual Enrollment :

83 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Masking Description:

double-blind, placebo-controlled

Primary Purpose:

Treatment

Official Title:

Gulf War Illness Inflammation Reduction Trial

Study Start Date :

Jul 1, 2015

Actual Primary Completion Date :

Dec 1, 2021

Actual Study Completion Date :

Mar 7, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Modified-Release Prednisone Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm	Drug: Modified-Release Prednisone Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks Other Names: Rayos
Placebo Comparator: Placebo Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm	Drug: Placebo Placebo oral tablets (2x5mg) daily for 8 weeks Other Names: sugar pill, inactive substance

Arm

Intervention/Treatment

Experimental: Modified-Release Prednisone

Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm

Drug: Modified-Release Prednisone

Modified-Release Prednisone oral tablets (2x5mg) daily for 8 weeks

Other Names:

Rayos

Placebo Comparator: Placebo

Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm

Drug: Placebo

Placebo oral tablets (2x5mg) daily for 8 weeks

Other Names:

sugar pill, inactive substance

Outcome Measures

Primary Outcome Measures

Change from baseline of Veterans RAND 36-Item Health Survey Physical Component Summary Score (PCS) scores at 8 and 16 weeks [0, 8, and 16 weeks]
PCS is a measure of HRQOL with respect to physical functioning and symptoms.

Secondary Outcome Measures

Change from baseline of McGill Pain Questionnaire-short form (MPQ) scores at 8 and 16 weeks [0, 8, and 16 weeks]
MPQ asks questions about sensory pain, affective pain, pain now, and typical pain
Change from baseline of Multidimensional Fatigue Inventory (MFI) scores at 8 and 16 weeks [0, 8, and 16 weeks]
MFI asks questions about general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue.
Change from baseline of Cognitive Failures Questionnaire (CFQ) scores at 8 and 16 weeks [0, 8, and 16 weeks]
CFQ asks questions about cognitive symptoms such as attention, concentration, and memory
Change from baseline of Veterans RAND 36-Item Health Survey Mental Component Summary Score (MCS) scores at 8 and 16 weeks [0, 8, and 16 weeks]
SF-36V MCS is a measure of HRQOL with respect to mental functioning
Change from baseline of Gulf War Illness-associated peripheral blood biomarkers [0, 8, and 16 weeks]
Peripheral blood biomarker levels are quantified by multi-analyte profiling (MAP) and complete blood count (CBC) analyses

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Scores moderate-severe on at least 3 out of 6 domains from the Kansas GWI Case Definition
Deployed, (and honorably discharged), from the Kuwaiti Theater of Operation (August 2, 1990-July 31, 1991)

Exclusion Criteria:

Hospitalization anytime since 1990 for Alcohol or Drug Dependence, Depression, or PTSD
Known hypersensitivity to Prednisone
Liver, (active or recent Hepatitis B or C treatment with a completion date within the past 6 months, or alcohol liver disease), or Kidney Disease (Hep B and C ok if after 6 months of treatment)
Treated Diabetes
Females who are Pregnant or Nursing
Female who refuses to use an accepted method of birth control
Exclusionary Labs: C-Reactive Protein >25, Creatinine Clearance <30, EFGR ≥ 30, Hgb A1-C >7, Glucose >120, WBC >12, RBC >6.2, Hematocrit >60, Hemoglobin <11, Platelets <100, Liver Function Tests (2 x the upper limit of AST and ALT, 2 x the upper limit of Total Bilirubin, and Alkaline Phosphatase)
Has Inflammatory Arthritis (RA, or Psoriatic Arthritis, Spondylitis, Polyarthritis)
Reactive Arthritis, or IBD associated Arthritis
Has any major inflammatory disease (acute Chronic Infections, Ulcerative Colitis, Crohn's Disease, Inflammatory lung diseases- COPD or Asthma requiring steroid treatment, Pericarditis, Vasculitis)
Has an chronic/active infection
Chronic use of Prednisone or Corticosteroids (occasional inhaled use of steroids acceptable)
Active Gum Disease or Dental Infection
Has been diagnosed with Lupus, Stroke, or Multiple Sclerosis. or any other diagnosis that produces symptoms of fatigue, cognitive impairment, or pain will be excluded based on the Kansas GWI Case definition
Has a condition that may interfere with the ability to accurately report symptoms, (Severe Psychiatric Problems, Schizophrenia, Bipolar Disorder, Alcohol or Drug Dependence requiring hospitalization, or regular illegal drug use)
Heart Disease (other than Hypertension), Heart Failure or Coronary Heart Disease requiring hospitalization within the past 12 months
Cancer (other than basal cell skin cancer), requiring treatment within the past 12 months, or life expectancy of less than 1 year.
Hospitalization within the past 3 months